AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID
Breakpoints
Antiflankens and a New Antiviral
The new anti funnels and then one new antiviral that I'm very that I actually am very excited about. The first is a novel or in oral glycan synthesis inhibitor, it recently got FDA approved at a dose of 300 milligrams twice a day for one day for full of vaginal candidiasis. It's nice because it can be administered weekly so it has this really long half life. And the solstice trial was finally published in CID which is looking at morebivir for refractory resistant CMV. This drug prevents CMV from replicating but it treats GAN cycle of your resistant isolates based on its different mechanism of action.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode